Bellerophon Therapeutics, Inc.
184 Liberty Corner Road, Suite 302
Warren, New Jersey 07059
November 2, 2017
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 3561
Washington, D.C. 20549
Attention: Suzanne Hayes, Assistant Director
Re: | Bellerophon Therapeutics, Inc. |
Registration Statement on Form S-3 | |
Filed on October 24, 2017 | |
File No. 333-221087 | |
Dear Ms. Hayes:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Bellerophon Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Monday, November 6, 2017, at 9:00 a.m., Eastern Time, or as soon as thereafter practicable.
Any questions should be addressed to Jeffrey Schultz, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York 10017, telephone (212) 692-6732.
Thank you very much.
Very truly yours, |
Bellerophon Therapeutics, Inc. |
/s/ Fabian Tenenbaum |
By: Fabian Tenenbaum |
Title: Chief Executive Officer |
cc: | Irene Paik, Securities and Exchange Commission |
Jeffrey Schultz, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. | |